Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026 in New York.
At the Cantor Global Healthcare Conference 2026, the company will join a fireside chat on September 9, 2026 at 3:20 PM ET and hold one-on-one investor meetings the same day. A live and replay link will be made available online.
At the H.C. Wainwright 28th Annual Global Investment Conference, InflaRx will present on September 14, 2026 at 10:00 AM ET and also conduct one-on-one meetings, with registration and replay access provided via an online link.
InflaRx (Nasdaq: IFRX) reported second quarter 2026 results and a strategic refocus on izicopan, its next-generation oral C5aR inhibitor, for ANCA-associated vasculitis (AAV) and select renal diseases including aHUS, IgAN and C3G. Phase 2 planning in AAV and open-label renal proof-of-concept studies are underway, with initial renal data targeted for 2027.
InflaRx plans a PK bridging study with izicopan in China in late 2026 to accelerate additional inflammation and immunology indications and intends to engage EMA on vilobelimab and izicopan in AAV following CHMP’s recommendation to revoke Tavneos’ EU marketing authorization. In May, the company completed a $150 million underwritten offering (75 million shares at $2.00), generating €119.3 million net, strengthening total funds to €158.4 million at June 30, 2026, which management expects will fund operations and development through 2029.
For the six months ended June 30, 2026, InflaRx recorded a net loss of €16.2 million (€0.17 per share), improved from €22.7 million (€0.35 per share) a year earlier, driven by lower R&D, sales and marketing, and G&A expenses.
InflaRx (Nasdaq: IFRX) announced it will report its second quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens. The company does not plan to hold a conference call in connection with this release.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement factor C5a and its receptor C5aR. Its lead oral small-molecule program, izicopan, is being developed for ANCA-associated vasculitis and additional renal diseases, while vilobelimab, an intravenously delivered monoclonal antibody, has shown clinical activity and tolerability in multiple studies.
InflaRx (Nasdaq: IFRX) is assessing a broadened ANCA-associated vasculitis (AAV) strategy in Europe after the EMA committee recommended revoking Tavneos’ EU authorization. The company plans EMA discussions on vilobelimab and oral izicopan, continues Phase 2 izicopan AAV planning, highlights Phase 2 vilobelimab AAV data, partner-led BDB-001 Phase 3 in China, and ongoing EU and US authorizations for GOHIBIC (vilobelimab) in COVID-19 ARDS.
InflaRx (Nasdaq: IFRX) closed an underwritten offering of 75,000,000 ordinary shares at $2.00 per share on May 8, 2026, raising aggregate gross proceeds of $150.0 million before underwriting discount and offering expenses. The company said net proceeds will fund pipeline activities, working capital and general corporate purposes.
InflaRx (Nasdaq: IFRX) priced an underwritten offering of 75,000,000 ordinary shares at $2.00 per share, for gross proceeds of approximately $150 million. The offering is expected to close on May 7, 2026, subject to customary closing conditions.
The company intends to use net proceeds to advance its pipeline activities and for working capital and general corporate purposes. Institutional participation includes several new and existing investors; Guggenheim Securities is lead bookrunner.
InflaRx (Nasdaq: IFRX) will develop izicopan in ANCA-associated vasculitis (AAV) and pursue rapid proof of concept in select life-threatening renal diseases (aHUS, IgAN, C3G).
The company is planning Phase 2 activity in AAV, open-label renal studies with data expected next year, a PK bridging study in China this year, and a Capital Markets Day in summer 2026. InflaRx estimates funding for planned programs and operations through 2029.
InflaRx (Nasdaq: IFRX) reported preclinical in vitro data showing low reactive metabolite formation for izicopan in human liver microsomes versus higher levels for avacopan. Differences exceeded 100-fold at 5–10 minutes and were ~10-fold at 20–40 minutes. InflaRx noted izicopan did not inhibit CYP3A4 in vitro and cited prior Phase 1 and Phase 2a safety and PK/PD data, including ≥90% blockade of C5a-induced neutrophil activation.
InflaRx cautioned that in vitro findings do not directly predict clinical outcomes but said the results support izicopan’s differentiated preclinical profile within the C5aR1 inhibitor class.
InflaRx (Nasdaq: IFRX) will release its first quarter 2026 financial and operating results on May 7, 2026 before the market opens. No conference call is planned. The company develops anti-inflammatory therapeutics including oral izicopan and intravenous vilobelimab, and has operations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1). The closing bid price was at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and Nasdaq closed the matter.
The company reiterated its lead programs, izicopan and vilobelimab, and listed investor contacts and subsidiaries.